{
  "trial_id": "NCT01693029",
  "trial_group": "chronic kidney disease",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, baseline hemoglobin level, baseline iron levels, duration of chronic kidney disease, duration of end-stage renal disease, baseline erythropoietin dose, comorbid conditions (e.g., diabetes, hypertension), baseline renal function (e.g., glomerular filtration rate), body mass index (BMI), baseline blood pressure, baseline serum creatinine, baseline albumin levels, baseline ferritin levels, baseline transferrin saturation, history of cardiovascular disease, smoking status, baseline liver function tests.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment",
        "Height",
        "Weight",
        "Primary cause of Chronic Kidney Disease (CKD)",
        "Type of last Erythropoiesis Stimulating Agent (ESA) therapy prior",
        "Time since start of ESA therapy",
        "Time since start of dialysis",
        "Method of dialysis at Baseline"
      ],
      "remaining_candidate_features": [
        "baseline hemoglobin level",
        "baseline iron levels",
        "duration of chronic kidney disease",
        "duration of end-stage renal disease",
        "baseline erythropoietin dose",
        "comorbid conditions (e.g., diabetes, hypertension)",
        "baseline renal function (e.g., glomerular filtration rate)",
        "baseline blood pressure",
        "baseline serum creatinine",
        "baseline albumin levels",
        "baseline ferritin levels",
        "baseline transferrin saturation",
        "history of cardiovascular disease",
        "smoking status",
        "baseline liver function tests."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Hemoglobin level, Iron status, Duration of anemia, Duration of chronic kidney disease, Concomitant medications, Baseline kidney function,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Height",
        "Weight",
        "BMI",
        "Primary cause of Chronic Kidney Disease (CKD)",
        "Type of last Erythropoiesis Stimulating Agent (ESA) therapy prior",
        "Time since start of ESA therapy",
        "Time since start of dialysis",
        "Method of dialysis at Baseline"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Hemoglobin level",
        "Iron status",
        "Duration of anemia",
        "Duration of chronic kidney disease",
        "Concomitant medications",
        "Baseline kidney function"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Hemoglobin level, Iron substitution, History of cardiovascular disease, History of malignancy, History of systemic lupus erythematous, History of immunocompromised status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "BMI",
          "Body Mass Index"
        ],
        [
          "Primary cause of Chronic Kidney Disease (CKD)",
          "Hemoglobin level"
        ],
        [
          "History of malignancy of any organ system",
          "History of malignancy"
        ],
        [
          "Systemic lupus erythematous",
          "History of systemic lupus erythematous"
        ],
        [
          "Immunocompromized patients",
          "History of immunocompromised status"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Height",
        "Weight",
        "Type of last Erythropoiesis Stimulating Agent (ESA) therapy prior",
        "Time since start of ESA therapy",
        "Time since start of dialysis",
        "Method of dialysis at Baseline"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Iron substitution",
        "History of cardiovascular disease"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of end stage renal disease (ESRD), duration of epoetin alfa therapy, mean hemoglobin level at screening, iron substitution status, presence of comorbidities (e.g. hypertension, diabetes, cardiovascular disease), New York Heart Association (NYHA) class, history of malignancy, history of immunocompromised state.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ],
        [
          "Time since start of ESA therapy",
          "duration of epoetin alfa therapy"
        ],
        [
          "Primary cause of Chronic Kidney Disease (CKD)",
          "duration of end stage renal disease (ESRD)"
        ],
        [
          "History of malignancy of any organ system",
          "history of malignancy"
        ],
        [
          "Immunocompromized patients",
          "history of immunocompromised state"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Height",
        "Weight",
        "Type of last Erythropoiesis Stimulating Agent (ESA) therapy prior",
        "Time since start of dialysis",
        "Method of dialysis at Baseline"
      ],
      "remaining_candidate_features": [
        "mean hemoglobin level at screening",
        "iron substitution status",
        "presence of comorbidities (e.g. hypertension, diabetes, cardiovascular disease)",
        "New York Heart Association (NYHA) class"
      ]
    }
  }
}